Decision Diagnostics in Receipt of Revised Cash Offer from Proposed M&A Partner, Enhanced by 21% Over Previously Disclosed Proposals

Decision Diagnostics Corp.

Industry:
Industrial & Manufacturing

Decision Diagnostics in Receipt of Revised Cash Offer from Proposed M&A Partner, Enhanced by 21% Over Previously Disclosed Proposals

LOS ANGELES, CA / ACCESSWIRE / September 7, 2017 / Decision Diagnostics Corp. (OTC PINK: DECN) is the FDA registered manufacturer, quality plan administrator, medical device customer support, and exclusive worldwide sales service and regulatory process agent for the GenUltimate! test strip and the new GenSure! test strip used in the testing of blood sugar to detect diabetes and pre-diabetes. DECN is also in advanced development of its GenChoice! and GenPrecis! test strips and meter. The company's GenPrecis! system, to be launched on January 1, 2018 is believed to be the most precise home testing glucose device to compete on the at-home diabetes testing market.

The company is pleased to announce that the Board of Directors has received a follow-on cash offer from its prestigious proposed M&A partner. The Board has determined to debate this offer just as soon as the initial launch of its new GenSure! product is complete.

Keith Berman, CEO of Decision Diagnostics commented, "On September 1, 2017 the Board of Directors received a revised confidential cash offer from our previously disclosed M&A partner. The revised offer is again substantially above our current stock price highlighting the faith and confidence our hopeful future partners have in our past successes and our projected sales on the two new products, GenSure! and GenChoice! and our current mainstay, the GenUltimate!."

Mr. Berman continued, "This new offer represents a 21% improvement over the proposals previously disclosed in July 2017, again highlighting the enthusiasm of the M&A candidate to become partnered us. Those who know DECN, know that we are extreme at vetting our partners and lenders and turn down many more offers than we have accepted, and it continues to work for us. The Board cautions shareholders to be patient and allow this process to come to its natural conclusion."

Forward-Looking Statements:

This release contains the company's forward-looking statements which are based on management's current expectations and assumptions as of September 5, 2017, regarding the company's business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.

CONTACT INFORMATION:

Decision Diagnostics Corp.
Keith Berman (805) 446-2973

Joanne Broeders (305) 340-1000
[email protected]
www.genultimate.com
www.pharmatechdirect.com

SOURCE: Decision Diagnostics Corp.